Chemo-brain
14
6
7
3
Key Insights
Highlights
Success Rate
75% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 37/100
7.1%
1 terminated out of 14 trials
75.0%
-11.5% vs benchmark
0%
0 trials in Phase 3/4
100%
3 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (14)
Impact of Supplementation With Synbiotics and Prebiotics on Cognitive Decline Associated With Neoadjuvant Chemotherapy in First-line Patients With Breast Cancer
Chemotherapy-induced Cognitive and Brain Changes in Older Adults With Breast Cancer
nCCR for Chemotherapy Related Cognitive Impairment Randomized Study
Improve Cancer-related Cognitive Impairment
Cognitive Impact Associated With Surgery For Gastric Or Esophageal Cancer
Cognitive Impairment in Colorectal Cancer Patients Receiving Cytotoxic Chemotherapy
Cognitive Impairment in Treated Breast Cancer Survivors: Possible Approaches
Investigating Cognitive Impairment in Young Patients With Cancer Prospectively
Memantine for Prevention of Cognitive Decline in Patients With Breast Cancer
Treatment of Post-Chemo Cognitive Impairment w/Transcranial Magnetic Stimulation (Chemobrain TMS)
Assessment of Brain Cognitive Impairment in Breast Cancer
Cognitive Status Assessment In Elderly Patients With Active Treatment For Haematological Malignancies
Nicotinic Treatment of Post-Chemotherapy Subjective Cognitive Impairment: A Pilot Study
Acupuncture Prevents Chemobrain in Breast Cancer Patients